Business Wire

PHENOM

5.5.2021 09:02:13 CEST | Business Wire | Press release

Share
Phenom Named Among First-Ever Strategic Leaders in Fosway’s 2021 9-Grid™ for Talent Acquisition

Phenom , the No. 1 provider of Talent Experience Management (TXM) solutions, has been recognized as a Strategic Leader in the 2021 Fosway 9-Grid™ for Talent Acquisition . Fosway identifies Strategic Leaders as companies that provide a rich suite of capability across a broad scope of features and have the sophistication to meet the needs of complex enterprise-scale customers. Additionally, these solutions achieve higher levels of customer impact and advocacy compared to alternatives in the market.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210505005153/en/

The Fosway Group 9-Grid™ report for Talent Acquisition indicates the relative position of solutions and providers in the European talent acquisition system space. Analyzing data from the pandemic-altered market, the 2021 report also indicates how well software solutions scaled and performed for customers during last year’s volatility.

The report identified several key market and solution trends, including:

  • THE GREAT REBOARD: Companies that lost jobs last year are pivoting to better recruitment technology to prepare for strategic, efficient rehiring.
  • CANDIDATE EXPERIENCE: Transparent communication and agile decision-making underlie positive candidate experiences for both hires and non-hires.
  • ARTIFICIAL INTELLIGENCE: Enterprises must leverage AI and automation in the hiring process to remain competitive.
  • DIVERSITY, EQUITY & INCLUSION : Employers are realizing that diversity, equity and inclusion commitments must be a centerpiece in their HR strategies.
  • VIDEO EXPERIENCES : Live video’s role in hiring will last beyond the pandemic, as companies realize it will be an efficient, authentic way to find best-fit candidates.
  • INTERVIEW SCHEDULING : Chatbot and AI reduce friction across the scheduling process, generating more meaningful interactions between candidates and recruiters.
  • TALENT MARKETPLACE : The most effective solutions need to include gigs, reskilling and upskilling for mutual employer/employee growth.
  • COLLABORATIVE HIRING : Increasing communication between recruiter and hiring manager workflows is encouraged through integrations with Microsoft Teams and Slack.

“Phenom’s focus on disrupting the candidate and hiring experiences, has resonated strongly with the market,” said David Wilson, CEO of Fosway. “Rapid growth in adoption in enterprise organisations, as well as expanded physical presence and multiple market acquisitions is further accelerating its success in Europe and globally. All of these warrant Phenom’s increased rating as a Strategic Leader for Talent Acquisition in 2021.”

In 2020, the Phenom platform was adopted by 25,000 recruiters, talent marketers and hiring managers — helping them hire over 2 million people and engage over 3 million employees.

The Phenom platform automates administrative tasks and personalizes experiences, generating more impactful moments throughout the talent journey. As a result, candidates find the right job faster; employees learn and evolve; recruiters discover best-fit talent with efficiency and scale; and managers make stronger data-driven decisions to build their future teams.

Kuehne+Nagel, a global logistics company and Phenom customer, continues to see new value in the Phenom platform every day.

“Through Phenom, we’ve been able to strengthen our centralized recruitment activities per hemisphere, build an external career site and adapt it to local markets, implement a CRM — and now level up our employee experience — to build the most sophisticated talent acquisition ecosystem there is to offer,” said Sandra Aasma, global HR systems expert at Kuehne+Nagel.

“As Phenom continues to expand across EMEA, we’re honored to be one of the first-ever Strategic Leaders in Fosway’s Talent Acquisition grid,” said Jeff Carey, senior vice president of international business at Phenom. “Our new position on the Fosway 9-grid™ signals that enterprises routinely pick Phenom — galvanized by our sophisticated AI-powered platform and steadfast commitment to customers. By constantly upgrading and launching new products, we always stay at the front of a rapidly evolving HR technology market.”

Over 100 companies across the EMEA market have adopted Phenom’s platform to upgrade their talent experiences. As demand for Talent Experience Management has spiked, Phenom recently acquired two Europe-based companies and opened an office in Munich to complement its European headquarters in Rotterdam. With over 100 employees based in countries including Germany, France, Ireland, the Netherlands, Switzerland, Italy, Spain and the United Kingdom, Phenom continues to solidify EMEA’s importance within the company’s ultimate growth strategy.

To learn more about Phenom’s Strategic Leader position, please visit their blog .

To see Fosway’s full analysis, check out their 2021 9-grid™ .

About Phenom

Phenom is a global HR technology company with a purpose to help a billion people find the right job. With an expertise in building AI-powered, scalable solutions, Phenom Talent Experience Management (TXM) personalizes and automates the talent journey for candidates, recruiters, employees and management with its Career Site, Chatbot, CRM, CMS, SMS and Email Campaigns, University Recruiting, Internal Mobility, Career Pathing, Diversity & Inclusion, Talent Marketplace, Gigs, Referrals, Hiring Manager and Analytics. As a result, employers improve their talent acquisition and talent management efforts by helping candidates and employees find the right job, recruiters identify and engage the right talent, and management optimizes HR strategy, process and spend. Phenom was ranked among the fastest-growing technology companies in the 2020 Deloitte Technology Fast 500, and won a regional 2020 Timmy Award for launching and optimizing HelpOneBillion.com.

Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.

For more information, please visit www.phenom.com . Connect with Phenom on LinkedIn , Twitter , Facebook , YouTube and Instagram .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye